Halozyme Therapeutics, Inc. (0J2O.L) LSE

68.84

-0.19(-0.28%)

Updated at December 24 05:27PM

Currency In USD

Valuation

Market Cap6.06B
Enterprise Value7.45B
P/E Ratio13.47
PEG Ratio1.47
Price/Sales Ratio6.47
Price/Book Ratio15.91
Enterprise/Revenue7.35
Enterprise/EBITDA10.31

Fiscal Year

Fiscal YearDecember 31, 2024
Most Recent QuarterSeptember 30, 2025

Profitability

Profit Margin0.48
Operating Margin0.59

Management Effectiveness

Return On Assets0.27
Return On Equity1.42

Income Statement

Revenue1.02B
Revenue/Share10.6
Gross Profit855.91M
EBITDA656.54M
Net Income444.09M
Diluted EPS3.43

Balance Sheet

Total Cash701.96M
Total Cash/Share5.99
Total Debt1.51B
Total Debt/Equity3
Current Ratio1.59
Book Value Per Share4.3

Price History

52-Week Change43.6
52-Week High69.38
52-Week Low30.09
Moving Average 50 Days36.88
Moving Average 200 Days37.43

Statistics

Average Volume1,670
Shares Outstanding117.6M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split FactorN/A
Last Split DateN/A